Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT)

Group 1 - The article discusses the investment potential of Altimmune, Inc. (ALT), focusing on its lead drug candidate, pemvidutide, which is the only drug in its pipeline [1] - The author emphasizes the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts and financial analyses for major pharmaceutical companies [1] Group 2 - The article is authored by a biotech consultant with over five years of experience in the industry, who has prepared detailed reports on more than 1,000 companies [1] - The newsletter aims to offer buy and sell ratings, as well as catalysts to monitor for investment opportunities in the biotech sector [1]